These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Emerging Therapies for Transthyretin Amyloidosis. Tsoi MR; Lin JH; Patel AR Curr Oncol Rep; 2023 Jun; 25(6):549-558. PubMed ID: 36943555 [TBL] [Abstract][Full Text] [Related]
14. A descriptive study of transthyretin amyloidosis in a tertiary hospital without a referral unit. Bueno Juana E; Gracia Gutiérrez A; Melero Polo J; Roteta Unceta-Barrenechea A; Andrés Gracia A; Lahuerta Pueyo C; Menao Guillén S; Revilla Martí P; Aibar Arregui MÁ Rev Clin Esp (Barc); 2022 Mar; 222(3):161-168. PubMed ID: 34563487 [TBL] [Abstract][Full Text] [Related]
15. Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis. Gopal DM; Ruberg FL; Siddiqi OK Curr Heart Fail Rep; 2019 Oct; 16(5):180-188. PubMed ID: 31520266 [TBL] [Abstract][Full Text] [Related]
16. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308 [TBL] [Abstract][Full Text] [Related]